Association between thyroid hormones and risk of overall and aggressive prostate cancer.

*<p>- Information on cancer stage and grade available for cases diagnosed through July 2002.</p>†<p>- Conditioned on age and date of baseline blood draw.</p>‡<p>- Conditioned on age and date of baseline blood draw. Further adjusted for body mass index (kg/m2), serum concentrations of retinol, total cholesterol, alpha-tocopherol, and beta-carotene, cigarettes smoked per day, years smoked, family history of prostate cancer, physical activity, education, marital status, urban residence, total intake of energy, dietary vitamin D, fruit, vegetables, red meat, alcohol, and use of calcium supplements.</p>§<p>- Hypothyroid defined as TSH >3 µIU/mL and T4 <4.6 µg/dL. Hyperthyroid defined as TSH <0.3 µIU/mL and T4 >12 µg/dL.</p

Age-adjusted^* baseline^† characteristics by quintile of baseline serum thyroxine (T4).

*<p>- Directly standardized to the age distribution of the entire cohort. Values are means unless otherwise indicated.</p>†<p>- All characteristics are from the baseline questionnaire except family history which was collected during follow-up and is available for 889 men in this case control set. Baseline dietary data were available for 1,117 men, and 246 men claimed supplement use at baseline.</p

Age-adjusted^* baseline^† characteristics by case-control status.

*<p>- Values are means unless otherwise indicated.</p>†<p>- All characteristics are from the baseline questionnaire except family history which was collected during follow-up and is available for 889 men in this case control set. Baseline dietary data were available for 1,117 men, and 246 men claimed supplement use at baseline.</p

Age-adjusted^* baseline^† characteristics by quintile of baseline serum thyroid stimulating hormone (TSH).

*<p>- Directly standardized to the age distribution of the entire cohort. Values are means unless otherwise indicated.</p>†<p>- All characteristics are from the baseline questionnaire except family history which was collected during follow-up and is available for 889 men in this case control set. Baseline dietary data were available for 1,117 men, and 246 men claimed supplement use at baseline.</p

Hypothyroid and hyperthyroid hormone profiles by serum concentrations of T4 and TSH.

<p>Hypothyroid and hyperthyroid hormone profiles by serum concentrations of T4 and TSH.</p

Baseline characteristics of men, ATBC Study.

<p>Medians (25^th, 75^th percentiles) are reported unless otherwise indicated.</p>*<p><i>P</i>-value for contrast between cases and controls by Wilcoxon rank sum test (medians) and Chi-square test (proportions).</p>†<p>Skin behavior in prolonged direct sunlight (self-reported).</p>‡<p>Light months = May–October, dark months = November–April.</p><p>Information on skin behavior and sun exposure was ascertained from a follow-up questionnaire which was missing for some men.</p

Adjusted odds ratios of melanoma by categories of serum 25(OH)D levels.

<p>OR, odds ratio; CI, confidence interval.</p><p>Conditional logistic regression models adjust for age at randomization, date of blood draw, height, weight, dietary cholesterol, and skin behavior (e.g., skin burns easily in prolonged direct sunlight (no/yes/missing)).</p><p>Darker months = November–April; lighter months = May–October.</p>*<p><i>P</i>-values based on test for trend.</p

Association of <i>Helicobacter pylori</i> (<i>H. pylori</i>) seropositivity with risk of lung adenocarcinoma and squamous cell carcinoma by time to diagnosis in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study.

<p>*Odds ratios (ORs) and 95% confidence intervals (CIs) were adjusted for baseline pack-years and total number of cigarettes per day.</p>†<p>Derived from a single model for CagA-seropositive and CagA-seronegative versus no <i>H. pylori</i> seropositivity for all cases diagnosed ≤9 years after baseline blood draw and their paired controls.</p>‡<p>Derived from a single model for CagA-seropositive and CagA-seronegative versus no <i>H. pylori</i> seropositivity for all cases diagnosed >9 years after baseline blood draw and their paired controls.</p

Lung cancer case and control selection for <i>Helicobacter pylori</i> serology testing within the ATBC cohort.

<p>*Individuals with nonmelanoma skin cancer were not excluded. †Eligible cases included all first primary lung squamous cell carcinoma or adenocarcinoma cases diagnosed at least 1 year after the baseline draw date through 30 July 2007. ‡Controls were matched one-to-one by age at baseline serum draw (+/−5 years) and date of baseline serum draw (+/−30 days). Controls had to be alive and cancer free at the date that the corresponding case was diagnosed.</p

Characteristics of randomly selected lung adenocarcinoma and squamous cell carcinoma cases and matched cancer-free controls from the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study.

<p>*Controls matched with cases on age at baseline serum draw and date of baseline serum draw.</p>†<p>BMI = body mass index.</p